Richard S Finn, MD
Abou-Alfa GK et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1(8). Abstract
Cheng AL et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862-73. Abstract
Finn RS et al. Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). ESMO 2022;Abstract LBA34.
Kudo M et al. Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. ESMO 2022;Abstract LBA36.
Reig M et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681-93. Abstract
Zhang T et al. The binding of an anti-PD-1 antibody to Fc-gamma-RI has a profound impact on its biological functions. Cancer Immunol Immunother 2018;67(7):1079-90. Abstract
Robin K Kelley, MD
Choueiri TK et al. FRACTION-RCC: Nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J Immunother Cancer 2022; 10(11):e005780. Abstract
Graham J et al. Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. Cancer Treat Rev 2022;110:102453. Abstract
Llovet JM et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3(4):386-401. Abstract
Reig M et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681-93. Abstract
Roessler D et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: A multicenter retrospective study. J Cancer Res Clin Oncol 2022;[Online ahead of print]. Abstract
Qin A et al. A phase I/II multisite study of rucaparib and pembrolizumab maintenance therapy in stage IV non-squamous non–small cell lung cancer after initial therapy with carboplatin, pemetrexed, and pembrolizumab. Gastrointestinal Cancers Symposium 2022;Abstract TPS9138.
Professor Arndt Vogel, MD
Deng R et al. Circulating HBV RNA: From biology to clinical applications. Hepatology 2022;76(5):1520-30. Abstract
Martin-Serrano MA et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 2022;[Online ahead of print]. Abstract
Oh D-Y et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. Gastrointestinal Cancers Symposium 2022;Abstract 378.
Oh DY et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1(8). Abstract
Oh DY et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). ESMO 2022;Abstract 56P.
Vogel A et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;[Online ahead of print]. Abstract
Vogel A, Saborowski A. Medical therapy of HCC. J Hepatol 2022;76(1):208-10. Abstract
Lipika Goyal, MD, MPhil
Berchuck JE et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann Oncol 2022;33(12):1269-83. Abstract
Goyal L et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388(3):228-39. Abstract
Goyal S et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med 2022;386(2):138-47. Abstract
Hollebecque A et al. Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. ESMO 2022;Abstract LBA12.
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). ASCO 2022;Abstract 4006.
Pant S et al. Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results. Gastrointestinal Cancers Symposium 2023;Abstract 610.
Subbiah V et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RETfusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1/2, open-label, basket trial. Lancet Oncol 2022;23(10):1261-73. Abstract